DT02 Rec'd PCT/PTO

2 2 FEB 2005

ereby certify that this correspondence is being deposited with the U.S. Postal rvice with sufficient postage as First Class Mail, in an envelope addressed to: 6 Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 313-1450, on the date shown below.

Dated: 2/17/05 Signature:

Under BON

Docket No.: CWRU-P03-015 (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gerson et al.

Application No.: 10/505400

August 19, 2004 Art Unit: N/A

Filed: August 19, 2004 Art Unit: N/

For: ALKYLATING AGENT COMBINATIONS

IN THE TREATMENT OF CANCER

Examiner: Not Yet Assigned

Confirmation No.: Not Yet Assigned

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Copies of the non-patent references on the PTO/SB/08 are provided.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/505400 Docket No.: CWRU-P03-015

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CWRU-P03-015. A duplicate copy of this paper is enclosed.

Dated: February 17, 2005

Respectfully submitted,

David P. Halstead

Registration No.: 44,735

ROPES & GRAY LLP One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Sub	Substitute for form 1449A/PTO		Complete if Known		
				Application Number	10/505,400
SUPPLEMENTAL INFORMATION			<b>IFORMATION</b>	Filing Date	August 19, 2004
	DISCLOSURE			First Named Inventor	Stanton L. Gerson
STATEMENT BY APPLICANT			APPLICANT	Art Unit	Not Yet Assigned
			/	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	CWRU-P03-015

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant	
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear	
	l		1			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			T <sup>6</sup>
						Γ

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See attached Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Initials	No.¹	publisher, city and/or country where published.  OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>	
	AE	Rosa et al., "Processing in vitro of an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites formed in vivo," Nucleic Acids Res. 19:5569-5574 (1991)		
	AD	Menissier-de Murcia et al., "Requirement of poly (ADP – ribose) polymerase in recovery from DNA damage in mice and in cells," Proc. Natl. Acad. Sci. USA 94:7303-7304 (1997)		
	AC	Liuzzi and Talpeart-Borle, "A new approach to the study of the base-excision repair pathway using methoxyamine," J. Biol. Chem. 260:5252-5258 (1985)		
	AB	53:1149-1155 (1993)  Fortini et al., Methoxyamine modification of abasic sites protects CHO cells from the cytotoxic and mutagenic effects of oxygen alkylation," Carcinogenesis 13: 87-93 (1992)		
	AA	Fortini et al., "Mutagenic processing of esthylation damage in mammalian cells: the use of methoxyamine to study apurinic/apyrimidinic site-induced mutagenesis," Cancer Res.		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.